| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 31, 2024 9:00 A.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 31, 2024 9:00 A.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $50.00 → $51.00 | Buy | H.C. Wainwright |
| 12/23/2024 | $50.00 | Buy | H.C. Wainwright |
| 5/20/2022 | $45.00 → $40.00 | Overweight | Cantor Fitzgerald |
| 6/30/2021 | $45.00 | Overweight | Cantor Fitzgerald |
FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026. Selected Fourth Quarter and Full Year 2025 Preliminary Financial Results (Unaudited): Net revenue for the fourth quarter of 2025 is expected to be in th
Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced that its BIASURGE® Advanced Surgical Solution ("BIASURGE") product has received an Innovative Technology contract from Vizient® Inc. ("Vizient"), the nation's largest provider-driven healthcare performance improvement company. The contract was awarded based on the
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, together with Biomimetic Innovations Ltd ("BMI"), today provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic™ Synthetic Injectable Structural Bio-Adhesive ("OsStic") to the U.S.
4 - Sanara MedTech Inc. (0000714256) (Issuer)
3 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
10-Q - Sanara MedTech Inc. (0000714256) (Filer)
H.C. Wainwright reiterated coverage of Sanara MedTech with a rating of Buy and set a new price target of $51.00 from $50.00 previously
H.C. Wainwright initiated coverage of Smtek with a rating of Buy and set a new price target of $50.00
Cantor Fitzgerald resumed coverage of Smtek with a rating of Overweight and set a new price target of $40.00 from $45.00 previously
Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the expansion of the Company's executive leadership team with new appointments. Elizabeth Taylor has been appointed to the position of Chief Financia
FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer. Zach Fleming, Sanara's Chief Executive Officer, stated, "Jake and Tyler are seasoned executives with a wealth of experience in the medical device and woun
FORT WORTH, TX, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary ("Zach") B. Fleming has been appointed Chief Executive Officer effective January 1, 2022. Ron Nixon, Sanara's Executive Chairman, stated, "Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy. During his time as President of the Surgical Division, he has overseen double-digit year over year revenue growth of our business and steered the division through the ch
SC 13G - Sanara MedTech Inc. (0000714256) (Subject)
Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary (2) ●Net revenue increased 22% to $26.3 million, compared to $21.7 million in the third quarter of 2024. ●Net income from continuing operations of $
FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its third quarter 2025 financial results on Wednesday, November 12, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on November 12, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended September 30, 2025 and hold a question and answer session at the end of the call. Th
Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary ●Net revenue increased 28% to